Disclosure of Events or Information
- Press Release - Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
- Completion of US FDA Inspection at Unit II of Apitoria Pharma Private Limited
- Entered into Agreement with GLS Pharma Limited to acquire balance 49% stake
- Eugia Steriles Pvt. Ltd. receives Establishment Inspection Report (EIR) from USFDA
- New injectable facility of Eugia Steriles Private Limited receives its first product approval by the US FDA
- Order received Deputy Commissioner for reversal of ITC and imposed penalty
- Unit III of Eugia Pharma Specialities Ltd. receives Warning Letter from US FDA
- Outcome of Board Meeting – 10.08.2024
- Press Release - USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg
- Classification of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd.
- Classification of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd.
- Outcome of Board Meeting – 18.07.2024 – Buyback
- Acquisition of Ace Laboratories Limited, UK
- Classification of US FDA Inspection at the injectable facility of Eugia SEZ Pvt. Ltd
- Execution of MSA between Merck Sharpe & Dohme Singapore Trading Pte. Ltd. and TheraNym Biologics Pvt.Ltd.
- Outcome of Board Meeting – 25.05.2024
- Classification of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd.
- Completion of US FDA Inspection at Unit VII of Apitoria Pharma Pvt.Ltd.
- Completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Limited.
- Purchase of shares held by JV partners in Purple Bellflower Pty Ltd
- Order received from Deputy Commissioner for Reversal of ITC and imposed penalty
- Completion of Disposal of business assets of Eugia US Manufacturing LLC
- A safety accident on April 6 in Unit 6 of Apitoria Pharma Pvt.Ltd.
- Completion of US FDA Inspection at the new injectable facility of Eugia Steriles Pvt.Ltd.
- Commencement of Commercial Production at four facilities including Penicillin-G
- Extension of timeline of LOI between Curateq and MSD upto 31.05.2024
- Aurobindo Pharma receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray
- Press Release - CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair)
- Restarting of distribution of aseptic products at Unit III of Eugia Pharma Specialities Ltd
- Acceptance of compliance with WHO GMP for APL Healthcare Ltd.
- Appointment of Mr.N.Ravikiran as Chief Business Officer
- Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
- Restarting of production in terminally sterilized product lines at Unit III of Eugia
- Completion of US FDA Inspection at the injectable facility of Eugia SEZ Pvt. Ltd
- Completion of US FDA Inspection at synthetic peptide API facility of Auro Peptides Ltd
- Aurobindo Pharma receives USFDA Approval for Deflazacort Tablets
- Outcome of Board Meeting – 10.02.2024
- Record Date for Payment of Second Interim Dividend 2023-24
- Disposal of Assets of Eugia US Manufacturing LLC
- Completion of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd
- Clarification to Stock Exchange – USFDA inspection in Unit-3 of Eugia
- CuraTeQ Biologics receives recommendation for grant of marketing authorization
- Classification of US FDA at Unit VI-B as VAI and receipt of EIR